6 The phosphodiesterase-five inhibitor sildenafil is certified for PAH in FC I–IV within the United states and FC II–III in Europe. Endothelin receptor antagonists (ERAs) such as bosentan, sitaxentan and ambrisentan are oral therapies certified to be used in PAH. As no oral agent has revealed superiority there remains discussion https://reidnjaqg.mybloglicious.com/47252360/tracleer-an-overview